CARDIFF LEXINGTON CORPORATION
Cardiff Lexington Corporation (CDIX)
Overview
Cardiff Lexington Corporation is a Nevada-incorporated micro-cap acquisition holding company that buys undervalued, undercapitalized businesses, primarily in healthcare, and provides them capital and management support. It trades over the counter (recently upgraded to the OTCQX Best Market in April 2026) under CDIX, with a market capitalization of roughly $3.9 million as of late August 2026 — down about 87% over the prior year. Fiscal 2025 revenue reached approximately $11.5 million, up nearly 40% year over year, but the company remains deeply unprofitable, with losses widening to about $6.5 million and an accumulated deficit north of $72.9 million. Auditors have included a going-concern qualification in recent filings, and management says it needs $5–10 million of additional capital to keep executing its acquisition strategy; the company engaged an investment bank in January 2026 to explore an S-1 filing and a Nasdaq uplisting.
What They Do & How They Make Money
Nearly all of Cardiff Lexington's revenue comes from its healthcare subsidiary, Nova Ortho and Spine, LLC (acquired May 2021), which operates a network of orthopedic and pain-management facilities and, more recently, ambulatory surgical centers across Florida — now including its 12th surgical center, Southeastern Surgery Center in Tallahassee, as part of a stated southeast/mid-Atlantic expansion push. Nova generates revenue from bodily-injury, general-liability, and personal-injury-protection (PIP) insurance claims tied to "plaintiff related care" — treating patients injured in auto accidents and similar incidents whose bills are ultimately paid out of settlements or insurance claims rather than Medicare/Medicaid. That model insulates Cardiff from direct government reimbursement pressure but exposes it to long, unpredictable collection cycles (management cites 18–24 months from treatment to cash, as receivables wait on lawsuit settlements) and to claim-realization risk — the company's own Q2 2026 update attributed a revenue decline to "fewer billed procedures and lower claim realization rates" even as patient volumes rose. A second, dormant subsidiary, Edge View Properties, holds about 23 acres of land in Salmon, Idaho, that management hopes to eventually develop through a joint venture, but it has generated essentially no revenue since 2021. Cardiff Lexington has also shed non-core assets, divesting its Platinum Tax Defenders tax-resolution business in 2023.
Competitors
Cardiff Lexington describes its competition on two levels. As an acquirer, it competes against larger private-equity firms, leveraged-buyout funds, and other roll-up holding companies for attractive small/mid-market healthcare deal flow — competitors with far greater capital resources. As an operator, Nova Ortho and Spine competes with other regional orthopedic, pain-management, and personal-injury-focused medical groups and surgical centers across Florida for both patients and referral relationships with personal-injury attorneys.
Competitive Position
Cardiff Lexington's position is that of a thinly capitalized serial acquirer whose survival depends heavily on a single operating subsidiary. Management argues its edge lies in operational experience, networks among small-to-mid-market healthcare targets, the advantages of being a public vehicle for sourcing and financing deals, and a governance structure that lets acquired-company management retain day-to-day control. In practice, however, the company shows almost none of the classic hallmarks of a durable moat: Nova's facilities operate at only about 35% of capacity even after several years of ownership, the underlying personal-injury-claims business model is commoditized and highly dependent on referral relationships and claims outcomes outside the company's control, and the balance sheet — a $72.9 million accumulated deficit, negative operating cash flow, and an explicit going-concern warning — leaves no cushion to withstand a slowdown or a failed acquisition. Revenue growth from adding surgical centers is a genuine positive, but until Cardiff Lexington demonstrates it can convert a larger network into sustained profitability and refinance away from going-concern territory, it remains a speculative, high-risk micro-cap rather than a business with structural competitive protection.